Skip to main content
Premium Trial:

Request an Annual Quote

NeoGenomics: Mark Mallon

NeoGenomics has announced that Mark Mallon is stepping down as CEO and a member of the board of directors, effective immediately. The decision was not the result of any disagreements about strategy with management or the board, inappropriate action by the CEO, or any violation of company policy or any accounting irregularity, the company said in a statement. 

Lynn Tetrault, the current chair of the board, has been appointed executive chairman and an interim office of the CEO has been established that includes CFO William Bonello, Chief Strategy and Corporate Development Officer Douglas Brown, and Chief Culture Officer Jennifer Balliet. Each executive will retain their current positions while carrying out new responsiblities, the company added.

The Scan

Polygenic Risk Score to Predict Preeclampsia, Gestational Hypertension in Pregnant Women

Researchers in Nature Medicine provide new mechanistic insights into the development of hypertensive disorders of pregnancy, which may help develop therapeutics.

New Oral Nanomedicine Strategy Targets Gut-Brain Axis to Treat IBD

A new paper in Science Advances describes a platform to design polyphenol-armored oral medicines that are effective at treating inflammatory bowel disease.

Phylogenetic Data Enables New Floristic Map

Researchers in Nature Communications use angiosperm phylogenetic data to refine the floristic regions of the world.

Machine Learning Helps ID Molecular Mechanisms of Pancreatic Islet Beta Cell Subtypes in Type 2 Diabetes

The approach helps overcome limitations of previous studies that had investigated the molecular mechanisms of pancreatic islet beta cells, the authors write in their Nature Genetics paper.